Symbols / CPIX $3.07 -0.97% Cumberland Pharmaceuticals Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NMS
CPIX Chart
About

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Drug Manufacturers - Spe Market Cap 45.92M
Enterprise Value 44.77M Income -2.84M Sales 44.52M
Book/sh 1.66 Cash/sh 0.77 Dividend Yield —
Payout 0.00% Employees 93 IPO —
P/E — Forward P/E 21.93 PEG —
P/S 1.03 P/B 1.85 P/C —
EV/EBITDA 33.08 EV/Sales 1.00 Quick Ratio 0.77
Current Ratio 1.01 Debt/Eq 41.48 LT Debt/Eq —
EPS (ttm) -0.19 EPS next Y 0.14 EPS Growth —
Revenue Growth 31.10% Earnings 2026-05-05 ROA -2.29%
ROE -12.17% ROIC — Gross Margin 85.02%
Oper. Margin -10.02% Profit Margin -6.37% Shs Outstand 14.96M
Shs Float 8.72M Short Float 1.64% Short Ratio 1.03
Short Interest — 52W High 6.27 52W Low 1.85
Beta -0.33 Avg Volume 148.11K Volume 18.52K
Target Price — Recom None Prev Close $3.10
Price $3.07 Change -0.97%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$3.07
Latest analyst target
3. DCF / Fair value
$7.75
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.07
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2019-12-03 main B. Riley Securities — → Buy $10
2019-11-18 main B. Riley Securities — → Buy $9
2018-08-17 main B. Riley Securities Buy → Buy $9
2018-04-17 init B. Riley Securities — → Buy $9
2013-04-10 main UBS — → Neutral $6
2012-11-12 main UBS — → Neutral $5
2012-11-09 down Wells Fargo Outperform → Market Perform —
News
RSS: Latest CPIX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-18 JONES JAMES R Director — 1,800 $2.80 $5,040
2026-03-18 YOUNG CAROLINE R Director — 1,800 $2.80 $5,040
2026-03-18 KROGULSKI KENNETH J Director — 5,800 $2.80 $16,240
2026-03-18 GALANTE JOSEPH C. Director — 1,800 $2.80 $5,040
2026-03-18 BROWN MARTIN S JR Director — 1,800 $2.80 $5,040
2025-12-31 JONES JAMES R Director — 270 $2.24 $799
2025-12-31 YOUNG CAROLINE R Director — 66 $2.24 $202
2025-12-31 KROGULSKI KENNETH J Director — 1,916 $2.24 $5,653
2025-12-31 KAZIMI A. J. Chief Executive Officer — 270 $2.24 $799
2025-11-28 JONES JAMES R Director — 302 $1.96 $664
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
44.52
+17.57%
37.87
-4.26%
39.55
-5.85%
42.01
Operating Revenue
40.40
+10.56%
36.54
-2.60%
37.51
-7.79%
40.68
Cost Of Revenue
6.67
+1.23%
6.59
+8.56%
6.07
-33.47%
9.12
Reconciled Cost Of Revenue
5.42
+2.36%
5.29
-37.00%
8.40
-5.18%
8.86
Gross Profit
37.85
+21.01%
31.28
-6.58%
33.49
+1.80%
32.89
Operating Expense
40.65
+7.77%
37.71
-12.37%
43.04
+11.51%
38.60
Research And Development
5.57
+15.58%
4.82
-17.45%
5.83
-12.78%
6.69
Selling General And Administration
31.05
+10.28%
28.15
-3.28%
29.10
+8.43%
26.84
Selling And Marketing Expense
19.10
+12.19%
17.02
-7.74%
18.45
+10.75%
16.66
General And Administrative Expense
11.95
+7.37%
11.13
+4.46%
10.65
+4.63%
10.18
Other Gand A
11.95
+7.37%
11.13
+4.46%
10.65
+4.63%
10.18
Total Expenses
47.31
+6.80%
44.30
-9.79%
49.11
+2.92%
47.72
Operating Income
-2.79
+56.59%
-6.43
+32.68%
-9.55
-67.48%
-5.70
Total Operating Income As Reported
-2.79
+56.59%
-6.43
+32.68%
-9.55
-67.48%
-5.70
EBITDA
2.97
+1528.47%
0.18
-92.66%
2.49
+646.58%
0.33
Normalized EBITDA
2.97
+5534.16%
-0.05
-103.29%
1.66
+697.57%
-0.28
Reconciled Depreciation
5.29
-12.53%
6.04
+4.73%
5.77
+8.30%
5.33
EBIT
-2.32
+60.50%
-5.86
-4.34%
-5.62
-12.45%
-5.00
Total Unusual Items
0.00
-100.00%
0.24
-71.15%
0.82
+34.43%
0.61
Total Unusual Items Excluding Goodwill
0.00
-100.00%
0.24
-71.15%
0.82
+34.43%
0.61
Special Income Charges
0.00
-100.00%
0.24
-71.15%
0.82
+34.43%
0.61
Other Special Charges
—
-0.24
+71.15%
-0.82
-34.43%
-0.61
Net Income
-2.84
+56.23%
-6.48
-3.19%
-6.28
-12.73%
-5.57
Pretax Income
-2.81
+56.53%
-6.47
-2.89%
-6.28
-12.61%
-5.58
Net Non Operating Interest Income Expense
-0.02
+92.90%
-0.27
+28.86%
-0.38
+21.86%
-0.49
Interest Expense Non Operating
0.50
-18.09%
0.61
-9.34%
0.67
+13.97%
0.59
Net Interest Income
-0.02
+92.90%
-0.27
+28.86%
-0.38
+21.86%
-0.49
Interest Expense
0.50
-18.09%
0.61
-9.34%
0.67
+13.97%
0.59
Interest Income Non Operating
0.48
+42.55%
0.33
+16.59%
0.29
+191.50%
0.10
Interest Income
0.48
+42.55%
0.33
+16.59%
0.29
+191.50%
0.10
Other Income Expense
—
0.24
-93.51%
3.65
+497.17%
0.61
Other Non Operating Income Expenses
—
—
2.83
—
Tax Provision
0.04
+277.58%
-0.02
-149.53%
0.05
-33.52%
0.07
Tax Rate For Calcs
0.00
+6076.47%
0.00
-98.38%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
0.00
-99.53%
0.17
+34.43%
0.13
Net Income Including Noncontrolling Interests
-2.86
+55.54%
-6.44
-1.78%
-6.33
-12.05%
-5.65
Net Income From Continuing Operation Net Minority Interest
-2.84
+56.23%
-6.48
-3.19%
-6.28
-12.73%
-5.57
Net Income From Continuing And Discontinued Operation
-2.84
+56.23%
-6.48
-3.19%
-6.28
-12.73%
-5.57
Net Income Continuous Operations
-2.86
+55.54%
-6.44
-1.78%
-6.33
-12.05%
-5.65
Net Income Discontinuous Operations
—
—
—
0.00
Minority Interests
0.03
+179.28%
-0.04
-170.08%
0.05
-35.53%
0.08
Normalized Income
-2.84
+57.77%
-6.72
+3.07%
-6.93
-14.46%
-6.05
Net Income Common Stockholders
-2.84
+56.23%
-6.48
-3.19%
-6.28
-12.73%
-5.57
Diluted EPS
-0.19
+58.70%
-0.46
-4.55%
-0.44
-15.79%
-0.38
Basic EPS
-0.19
+58.70%
-0.46
-4.55%
-0.44
-15.79%
-0.38
Basic Average Shares
14.85
+5.65%
14.06
-1.67%
14.30
-1.82%
14.56
Diluted Average Shares
14.85
+5.65%
14.06
-1.67%
14.30
-1.82%
14.56
Diluted NI Availto Com Stockholders
-2.84
+56.23%
-6.48
-3.19%
-6.28
-12.73%
-5.57
Amortization
4.03
-15.03%
4.75
-41.40%
8.10
+59.90%
5.07
Amortization Of Intangibles Income Statement
4.03
-15.03%
4.75
-41.40%
8.10
+59.90%
5.07
Depreciation Amortization Depletion Income Statement
4.03
-15.03%
4.75
-41.40%
8.10
+59.90%
5.07
Depreciation And Amortization In Income Statement
4.03
-15.03%
4.75
-41.40%
8.10
+59.90%
5.07
Earnings From Equity Interest Net Of Tax
-0.01
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
76.82
+1.64%
75.58
-7.57%
81.78
-12.00%
92.93
Current Assets
37.06
+1.67%
36.45
+2.07%
35.71
-22.14%
45.87
Cash Cash Equivalents And Short Term Investments
11.44
-36.29%
17.96
-1.95%
18.32
-7.27%
19.76
Cash And Cash Equivalents
11.44
-36.29%
17.96
-1.95%
18.32
-7.27%
19.76
Receivables
16.94
+44.81%
11.70
+19.91%
9.76
-25.87%
13.16
Accounts Receivable
16.94
+44.81%
11.70
+19.91%
9.76
-25.87%
13.16
Gross Accounts Receivable
25.94
+102.67%
12.80
+23.59%
10.36
-24.74%
13.76
Allowance For Doubtful Accounts Receivable
-9.00
-718.18%
-1.10
-83.33%
-0.60
+0.00%
-0.60
Inventory
6.23
+55.64%
4.00
-13.22%
4.61
-53.27%
9.86
Raw Materials
9.83
-17.94%
11.98
-5.05%
12.62
-2.17%
12.90
Finished Goods
5.65
+94.88%
2.90
-37.63%
4.65
+7.47%
4.32
Prepaid Assets
—
—
—
—
Other Current Assets
2.45
-12.25%
2.79
-7.89%
3.03
-1.94%
3.08
Total Non Current Assets
39.76
+1.62%
39.13
-15.05%
46.06
-2.11%
47.05
Net PPE
8.61
+33.38%
6.45
-8.35%
7.04
+27.98%
5.50
Gross PPE
11.11
+25.60%
8.85
-4.68%
9.28
+22.31%
7.59
Accumulated Depreciation
-2.50
-4.62%
-2.39
-6.87%
-2.24
-7.33%
-2.09
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
—
—
—
—
Machinery Furniture Equipment
1.93
+4.41%
1.84
+2.17%
1.81
+14.13%
1.58
Leases
9.19
+31.18%
7.00
-6.33%
7.48
+24.46%
6.01
Goodwill And Other Intangible Assets
14.94
-20.89%
18.89
-19.70%
23.52
-25.34%
31.50
Goodwill
0.91
+0.00%
0.91
+0.00%
0.91
+0.00%
0.91
Other Intangible Assets
14.03
-21.95%
17.97
-20.50%
22.61
-26.10%
30.59
Investments And Advances
3.99
0.00
—
—
Other Non Current Assets
12.23
-11.34%
13.79
-11.02%
15.50
+54.24%
10.05
Total Liabilities Net Minority Interest
52.28
-1.43%
53.04
+0.99%
52.52
-7.79%
56.95
Current Liabilities
36.74
+16.20%
31.62
+13.01%
27.98
-2.09%
28.58
Payables And Accrued Expenses
21.35
+33.56%
15.99
-5.10%
16.85
+13.56%
14.84
Payables
18.57
+33.44%
13.91
-0.88%
14.04
+29.75%
10.82
Accounts Payable
18.57
+33.44%
13.91
-0.88%
14.04
+29.75%
10.82
Current Accrued Expenses
2.79
+34.34%
2.07
-26.19%
2.81
-30.06%
4.02
Pensionand Other Post Retirement Benefit Plans Current
1.48
+23.17%
1.20
+0.25%
1.20
-16.87%
1.44
Current Debt And Capital Lease Obligation
0.47
-91.43%
5.46
+1467.55%
0.35
+101.31%
0.17
Current Debt
—
5.10
—
—
Other Current Borrowings
—
5.10
—
—
Current Capital Lease Obligation
0.47
+31.21%
0.36
+2.42%
0.35
+101.31%
0.17
Current Deferred Liabilities
0.03
-87.93%
0.21
-6.05%
0.22
-64.14%
0.61
Other Current Liabilities
13.42
+53.03%
8.77
-6.40%
9.37
-18.64%
11.52
Total Non Current Liabilities Net Minority Interest
15.53
-27.46%
21.42
-12.71%
24.53
-13.53%
28.37
Long Term Debt And Capital Lease Obligation
9.71
-35.75%
15.12
-16.40%
18.08
-13.02%
20.79
Long Term Debt
5.24
-48.50%
10.18
-20.40%
12.78
-21.09%
16.20
Long Term Capital Lease Obligation
4.47
-9.47%
4.94
-6.73%
5.30
+15.48%
4.59
Non Current Deferred Liabilities
3.38
+6.44%
3.17
+9.59%
2.89
+14.76%
2.52
Other Non Current Liabilities
0.25
+0.00%
0.25
-8.76%
0.27
+109.16%
0.13
Stockholders Equity
24.88
+8.87%
22.85
-22.80%
29.60
-18.37%
36.27
Common Stock Equity
24.88
+8.87%
22.85
-22.80%
29.60
-18.37%
36.27
Capital Stock
51.68
+10.39%
46.82
-0.57%
47.09
-0.81%
47.47
Common Stock
51.68
+10.39%
46.82
-0.57%
47.09
-0.81%
47.47
Share Issued
14.96
+7.20%
13.95
-1.20%
14.12
-1.70%
14.37
Ordinary Shares Number
14.96
+7.20%
13.95
-1.20%
14.12
-1.70%
14.37
Retained Earnings
-26.80
-11.83%
-23.97
-37.05%
-17.49
-56.02%
-11.21
Minority Interest
-0.34
-9.29%
-0.31
+10.49%
-0.34
-17.61%
-0.29
Total Equity Gross Minority Interest
24.54
+8.86%
22.55
-22.95%
29.26
-18.66%
35.97
Total Capitalization
30.12
-8.81%
33.03
-22.08%
42.39
-19.21%
52.47
Working Capital
0.32
-93.47%
4.83
-37.53%
7.73
-55.28%
17.29
Invested Capital
30.12
-21.00%
38.13
-10.05%
42.39
-19.21%
52.47
Total Debt
10.18
-50.51%
20.57
+11.63%
18.43
-12.07%
20.96
Capital Lease Obligations
4.94
-6.73%
5.30
-6.17%
5.64
+18.60%
4.76
Net Tangible Assets
9.94
+150.59%
3.97
-34.79%
6.08
+27.72%
4.76
Tangible Book Value
9.94
+150.59%
3.97
-34.79%
6.08
+27.72%
4.76
Inventories Adjustments Allowances
-9.25
+15.92%
-11.01
+14.05%
-12.80
-70.11%
-7.53
Line Of Credit
—
—
—
—
Non Current Accrued Expenses
2.20
-23.70%
2.88
-12.40%
3.28
-33.39%
4.93
Other Inventories
—
0.13
-15.77%
0.15
-11.38%
0.17
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
4.93
+905.72%
-0.61
-110.05%
6.09
-27.91%
8.45
Cash Flow From Continuing Operating Activities
4.93
+905.72%
-0.61
-110.05%
6.09
-27.91%
8.45
Cash From Discontinued Operating Activities
—
—
—
0.00
Net Income From Continuing Operations
-2.86
+55.54%
-6.44
-1.78%
-6.33
-12.05%
-5.65
Depreciation Amortization Depletion
5.29
-12.53%
6.04
+4.73%
5.77
+8.30%
5.33
Depreciation
1.25
-3.38%
1.30
-77.56%
5.77
+8.30%
5.33
Amortization Cash Flow
4.03
-15.03%
4.75
—
5.07
Depreciation And Amortization
5.29
-12.53%
6.04
+4.73%
5.77
+8.30%
5.33
Amortization Of Intangibles
4.03
-15.03%
4.75
—
5.07
Other Non Cash Items
-0.07
+95.96%
-1.81
-5.83%
-1.71
+19.06%
-2.11
Stock Based Compensation
0.41
+35.25%
0.30
-17.30%
0.37
-18.43%
0.45
Asset Impairment Charge
—
0.00
-100.00%
3.34
0.00
Deferred Tax
—
—
—
0.00
Deferred Income Tax
—
—
—
0.00
Operating Gains Losses
0.01
+391.27%
0.00
-86.72%
0.02
—
Gain Loss On Investment Securities
0.01
—
—
—
Change In Working Capital
2.16
+67.26%
1.29
-72.10%
4.63
-55.61%
10.44
Change In Receivables
-5.24
-169.82%
-1.94
-157.07%
3.40
+155.68%
-6.12
Changes In Account Receivables
-5.24
-169.82%
-1.94
-157.07%
3.40
+155.68%
-6.12
Change In Inventory
2.24
-6.88%
2.41
+10506.59%
-0.02
-102.54%
0.91
Change In Payables And Accrued Expense
6.71
+776.77%
-0.99
-126.62%
3.72
-74.38%
14.54
Change In Payable
6.71
+776.77%
-0.99
-126.62%
3.72
-74.38%
14.54
Change In Account Payable
6.71
+776.77%
-0.99
-126.62%
3.72
-74.38%
14.54
Change In Other Current Assets
-0.23
-222.59%
0.19
+187.91%
0.07
-90.47%
0.69
Change In Other Current Liabilities
-1.31
-180.58%
1.63
+164.27%
-2.54
-704.49%
0.42
Investing Cash Flow
-4.71
-8236.82%
0.06
+154.73%
-0.11
+99.23%
-13.67
Cash Flow From Continuing Investing Activities
-4.71
-8236.82%
0.06
+154.73%
-0.11
+99.23%
-13.67
Net PPE Purchase And Sale
-0.10
-47.31%
-0.07
+76.37%
-0.28
-175.35%
-0.10
Purchase Of PPE
-0.10
-47.31%
-0.07
+76.37%
-0.28
-175.35%
-0.10
Capital Expenditure
-0.18
-1.44%
-0.18
+60.33%
-0.45
+78.15%
-2.07
Net Investment Purchase And Sale
-4.48
0.00
—
0.00
Purchase Of Investment
-4.48
0.00
—
0.00
Sale Of Investment
—
—
—
—
Net Business Purchase And Sale
—
—
0.00
+100.00%
-13.50
Purchase Of Business
—
—
0.00
+100.00%
-13.50
Net Intangibles Purchase And Sale
-0.08
+25.47%
-0.11
+34.07%
-0.17
+91.29%
-1.97
Purchase Of Intangibles
-0.08
+25.47%
-0.11
+34.07%
-0.17
+91.29%
-1.97
Net Other Investing Changes
-0.05
-119.78%
0.24
-31.61%
0.35
-81.71%
1.90
Financing Cash Flow
-6.75
-3525.79%
0.20
+102.65%
-7.42
-260.10%
-2.06
Cash Flow From Continuing Financing Activities
-6.75
-3525.79%
0.20
+102.65%
-7.42
-260.10%
-2.06
Net Issuance Payments Of Debt
-10.04
-502.70%
2.49
+172.95%
-3.42
-384.65%
1.20
Issuance Of Debt
0.00
-100.00%
38.49
+22.28%
31.48
-40.50%
52.90
Repayment Of Debt
-10.04
+72.12%
-36.00
-3.17%
-34.89
+32.51%
-51.70
Long Term Debt Issuance
0.00
-100.00%
38.49
+22.28%
31.48
-40.50%
52.90
Long Term Debt Payments
-10.04
+72.12%
-36.00
-3.17%
-34.89
+32.51%
-51.70
Net Long Term Debt Issuance
-10.04
-502.70%
2.49
+172.95%
-3.42
-384.65%
1.20
Short Term Debt Issuance
—
—
—
—
Short Term Debt Payments
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
5.00
+963.98%
-0.58
+21.81%
-0.74
+29.68%
-1.05
Common Stock Payments
-0.26
+54.50%
-0.58
+21.81%
-0.74
+29.68%
-1.05
Repurchase Of Capital Stock
-0.26
+54.50%
-0.58
+21.81%
-0.74
+29.68%
-1.05
Net Other Financing Charges
-1.71
+0.18%
-1.72
+47.49%
-3.27
-47.96%
-2.21
Changes In Cash
-6.52
-1723.94%
-0.36
+75.11%
-1.44
+80.28%
-7.28
Beginning Cash Position
17.96
-1.95%
18.32
-7.27%
19.76
-26.93%
27.04
End Cash Position
11.44
-36.29%
17.96
-1.95%
18.32
-7.27%
19.76
Free Cash Flow
4.75
+699.85%
-0.79
-114.04%
5.64
-11.58%
6.38
Interest Paid Supplemental Data
0.44
-22.41%
0.57
-12.04%
0.65
+23.70%
0.52
Income Tax Paid Supplemental Data
—
0.01
-86.22%
0.11
+3197.67%
0.00
Common Stock Issuance
5.27
0.00
—
—
Issuance Of Capital Stock
5.27
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category